Quote

RHEL RHEL

—

Price & news catalysts

No price data available for RHEL.

What moved RHEL

No scored catalysts in the window yet.

Key statistics

Market cap

—

P/E

—

EPS

—

Beta

—

52W range

—

Day range

—

Open

—

Prev close

—

Volume

—

Avg volume

—

Dividend

—

IPO

—

Latest RHEL news

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease Trial Design
https://www.newsfilecorp.com/release/310598/Rhelion-Life-Sciences-Wholly-Owned-Subsidiary-Filament-Health-Signs-Letter-of-Intent-with-Darmiyan-Inc.-to-Explore-Use-of-FDA-De-Novo-Authorized-BrainSeeR-AI-Platform-in-Early-Alzheimers-Disease-Trial-Design · 8/20/2026+0.80

Profile

Sector: —
Industry: —
CEO: —
Employees: —
Country: —

Free · No account

Track these names every morning.

Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.

We’ll watch

$RHEL

Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.

Free forever · one email a day, max · unsubscribe in one click.How it works